KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Castle Biosciences (CSTL) Non-Current Receivables (2018 - 2025)

Castle Biosciences' Non-Current Receivables history spans 7 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Non-Current Receivables rose 104.58% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 104.58%, while the annual FY2025 figure was $1.9 million, 104.58% up from the prior year.
  • Non-Current Receivables for Q4 2025 was $1.9 million at Castle Biosciences, down from $2.0 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $2.0 million in Q3 2025 and bottomed at $918000.0 in Q4 2024.
  • The 5-year median for Non-Current Receivables is $1.2 million (2023), against an average of $1.3 million.
  • The largest annual shift saw Non-Current Receivables dropped 22.92% in 2024 before it surged 104.58% in 2025.
  • A 5-year view of Non-Current Receivables shows it stood at $1.3 million in 2021, then fell by 16.9% to $1.1 million in 2022, then increased by 9.57% to $1.2 million in 2023, then decreased by 22.92% to $918000.0 in 2024, then surged by 104.58% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Non-Current Receivables are $1.9 million (Q4 2025), $2.0 million (Q3 2025), and $1.1 million (Q2 2025).